They're patients, too: UCB employees share their own stories in fall campaign

UCB, with U.S. headquarters in Atlanta (shown), invited employees to share why they put "patients at the heart" in new digital campaign. (known per OTRS [Public domain])

At some point in life, everyone will be a patient. That’s one of the core drivers behind UCB's campaign featuring its own employees’ diverse experiences as patients, caregivers and dedicated researchers.

Called “Patients at the Heart,” the effort is a five-part digital series highlighting 10 stories that show what motivates UCB employees to put patients at the heart of their work.

It began as an internal effort to generate understanding and learn from each other what motivates the people sitting next to them. But then, it was so popular that UCB decided to share the stories outside the building, Allyson Funk, head of U.S. communications and public relations, said.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Cimzia maker UCB signs MyHealthTeams to pump up spondyloarthritis social network

The digital and social media campaign is running on UCB’s website as well as its Twitter, Facebook and LinkedIn. The work shows the outside world who’s working for UCB, including a father of a son with severe food allergies, a heart attack survivor and scientists determined to find the next cure.

Along with the external digital campaign, the stories and images will run on campus video boards at UCB's Atlanta headquarters and also at offices in Boston, Seattle, Washington, D.C., and Raleigh, North Carolina. The campaign will run through October, with more stories to be unveiled over the next months.

RELATED: UCB sponsors drive for clinical care standard for pregnant IBD patients

“What’s been most interesting and impactful for me personally is to recognize that you may sit and work next to someone every day and they may have an underlying motivation for why they’re in this industry that you weren’t aware of. Being able to pull that out and share that has been a really great way to connect with people and validate the types of experiences people bring to their everyday work,” Funk said.

UCB currently markets 10 drugs, five of which are in neurology. Its most recently approved drug, through a partnership with Amgen, is Evenity, a therapy for osteoporosis in postmenopausal women at high risk of fracture.

Suggested Articles

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

The FTC has sent Elanco a "second request" for details of the acquisition, signaling antitrust concerns about the $7.6 billion deal.